Tanvex (6541) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 泰福-KY

Tanvex (6541) reported revenue of NT$53.2 million for Oct 2026, +13.7% year on year and +67.1% from the previous month. Revenue for Jan–Oct 2026 was NT$565.3 million (+110.3% year on year).

In Oct 2026, it ranked No. 96 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$986,00024/10Nov 2024 NT$1.3 millionDec 2024 NT$499,000Jan 2025 NT$3.3 millionFeb 2025 NT$7.1 million25/02Mar 2025 NT$39.4 millionApr 2025 NT$8.6 millionMay 2025 NT$11.7 millionJun 2025 NT$26.6 million25/06Jul 2025 NT$16.9 millionAug 2025 NT$23.6 millionSep 2025 NT$84.9 millionOct 2025 NT$46.8 million25/10Nov 2025 NT$112 millionDec 2025 NT$20.1 millionJan 2026 NT$17.6 millionFeb 2026 NT$22.7 million26/02Mar 2026 NT$92.5 millionApr 2026 NT$86.8 millionMay 2026 NT$36.1 millionJun 2026 NT$97.6 million26/06Jul 2026 NT$53.8 millionAug 2026 NT$73.2 millionSep 2026 NT$31.9 millionOct 2026 NT$53.2 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$53.2 million+13.7%+67.1%
Sep 2026NT$31.9 million-62.4%-56.5%
Aug 2026NT$73.2 million+210.1%+36.1%
Jul 2026NT$53.8 million+218.6%-44.9%
Jun 2026NT$97.6 million+267.4%+170.4%
May 2026NT$36.1 million+208.2%-58.4%
Apr 2026NT$86.8 million+914.9%-6.1%
Mar 2026NT$92.5 million+134.7%+306.9%
Feb 2026NT$22.7 million+218.7%+28.7%
Jan 2026NT$17.6 million+428.9%-12.3%
Dec 2025NT$20.1 million+3,933.7%-82.0%
Nov 2025NT$112 million+8,351.6%+139.1%
Oct 2025NT$46.8 million+4,650.6%-44.8%
Sep 2025NT$84.9 million+3,916.1%+259.6%
Aug 2025NT$23.6 million+1,611.1%+39.8%
Jul 2025NT$16.9 million+110.7%-36.4%
Jun 2025NT$26.6 million+997.6%+126.9%
May 2025NT$11.7 million-9.2%+36.9%
Apr 2025NT$8.6 million+403.7%-78.3%
Mar 2025NT$39.4 million+6,084.6%+452.6%
Feb 2025NT$7.1 million+985.1%+113.6%
Jan 2025NT$3.3 million+61.8%+568.7%
Dec 2024NT$499,000-64.8%-62.3%
Nov 2024NT$1.3 million-81.0%+34.4%
Oct 2024NT$986,000+39.5%-53.3%

Jan–Oct 2026 cumulative: NT$565.3 million (+110.3% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Tanvex vs PEC / Tanvex vs Lotus Pharm / Tanvex vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

CDMO業務主要採完工比例認列,依投入工時計算。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16